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Background
Oral histamine receptor–1 antagonists, such as fexofena-
dine, offer suboptimal relief of allergic rhinitis-associated
nasal congestion. Combinations with oral sympathomi-
metics, such as pseudoephedrine, relieve congestion but
produce side effects. Histamine receptor-3 antagonists,
such as PF-03654764, reduce congestion in animals and
have been proposed as novel therapeutics. Previous nasal
allergen challenge studies of similar H1+H3 receptor
antagonist combinations demonstrated reduced conges-
tion. Herein we employ the Environmental Exposure Unit
(EEU) to conduct the first randomized controlled trial of
PF-03654764 in allergic rhinitis. The primary objective
was to compare the effect of PF-03654764+fexofenadine
to pseudoephedrine+fexofenadine on the subjective
measures of congestion and Total Nasal Symptom Score
(TNSS). The objective of post-hoc analyses were to
compare all treatments to placebo and determine the
onset of action (OA).
Methods
64 participants were randomized in a double-blind,
placebo-controlled 4-period crossover study. Participants
were exposed to ragweed pollen for 6 hours post-dose in
the EEU.
Results
PF-03654764+fexofenadine was not superior to pseudoe-
phedrine+fexofenadine. In post-hoc analyses, PF-03654764
+fexofenadine significantly reduced TNSS, relative to
placebo, and OA was 60 minutes. Pseudoephedrine+fexo-
fenadine significantly reduced congestion and TNSS,
relative to placebo, with OA of 60 and 30 minutes,
respectively. All PF-03654764-treated groups experi-
enced an elevated incidence of adverse events.
Conclusions
PF-03654764+fexofenadine failed to provide superior
relief of allergic rhinitis-associated nasal symptoms upon
exposure to ragweed pollen compared to fexofenadine
+pseudoephedrine. However, PF-03654764+fexofenadine
improved TNSS compared to placebo. Side effects were
not insignificant.
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